Moderna's experimental flu vaccine late-stage trial results are positive
Moderna (MRNA.US) announced on Monday that its experimental mRNA-based flu vaccine showed a stronger immune response in late-stage trials compared to currently available vaccines, paving the way for the development of this product as well as the company's standalone flu and COVID-19 vaccine combination. The stock price rose over 3% in pre-market trading.
The company stated that based on the new data, it plans to resubmit the application for the combination vaccine later this year and seek approval for its standalone flu vaccine. If regulators approve the flu vaccine, the company can advance the development of the combination vaccine
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments